Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

1997333 citationsJournal Article

Authors

A. Horwich · Medical Research Council

D.Th. Sleijfer · European Organisation for Research and Treatment of Cancer

Sophie D. Fosså · European Organisation for Research and Treatment of Cancer

Stan B. Kaye · European Organisation for Research and Treatment of Cancer

R.T.D. Oliver · European Organisation for Research and Treatment of Cancer

M.H. Cullen · European Organisation for Research and Treatment of Cancer

Abstract

With these drug doses and schedules, combination chemotherapy based on carboplatin was inferior to that based on cisplatin. This BEP regimen that contains moderate doses of etoposide and bleomycin is effective in the treatment of patients with good-prognosis metastatic nonseminoma.

Topics & Keywords

Testicular diseases and treatments Neuroblastoma Research and Treatments Cancer therapeutics and mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 15, Issue 5, pp. 1844-1852

DOI: 10.1200/jco.1997.15.5.1844

Field-Weighted Citation Impact: 14.85